← 返回

杀伤细胞免疫球蛋白样受体和体细胞突变对急性髓系白血病移植结局的影响

英文原题:Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.

查看英文原题

Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.

PubMed 2021/08/08(内容时间) Transplant Cell Ther Q1 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞受杀伤细胞免疫球蛋白样受体(KIR)与人白细胞抗原I类配体之间相互作用的调控。多种NK细胞异体反应模型被用于解释异基因造血细胞移植(alloHCT)后的结局,但研究结果差异很大。

我们假设,结合KIR谱分析急性髓系白血病(AML)的体细胞突变,可能进一步明确其与移植结局的关联。在这项单中心回顾性观察研究中,纳入81例接受亲缘相合供者alloHCT的AML患者。采用Kaplan-Meier法和log-rank检验,根据突变状态及KIR谱评估移植后结局。多变量分析显示,存在任意体细胞突变且C1/C2杂合的患者,急性移植物抗宿主病(GvHD)较少(风险比[HR]0.32;95%置信区间[CI]0.14–0.75;P=0.009)、复发较多(HR 3.02;95% CI 1.30–7.01;P=0.010)、无复发生存期(RFS)较差(HR 2.22;95% CI 1.17–4.20;P=0.014),总生存期(OS)也较差(HR 2.21;95% CI 1.17–4.20;P=0.015);而缺失KIR配体者RFS较优(HR 0.53;95% CI 0.30–0.94;P=0.031)。

存在体细胞突变且供者单倍型为A也与急性GvHD较少(HR 0.38;95% CI 0.16–0.92;P=0.032)、复发较多(HR 2.72;95% CI 1.13–6.52;P=0.025)、RFS较差(HR 2.11;95% CI 1.07–4.14;P=0.030)和OS较差(HR 2.20;95% CI 1.11–4.38;P=0.024)相关。增强NK细胞异体反应——即供者B单倍型提供更多KIR激活信号,且受者缺失KIR配体或C1或C2纯合导致抑制信号减少——可能有助于减轻部分AML体细胞突变相关的不良预后。这些结果可能有助于移植前改善患者风险分层并优化供者选择。

展开英文摘要原文

Natural killer (NK) cells are regulated by killer immunoglobulin-like receptor (KIR) interactions with human leukocyte antigen class I ligands. Various models of NK cell alloreactivity have been associated with outcomes after allogeneic hematopoietic cell transplant (alloHCT), but results have varied widely.

We hypothesized that somatic mutations in acute myeloid leukemia (AML) in the context of KIR profiles may further refine their association with transplant outcomes. In this single-center, retrospective, observational study, 81 AML patients who underwent matched-related donor alloHCT were included. Post-HCT outcomes were assessed based on mutational status and KIR profiles with the Kaplan-Meier method and log-rank test. On multivariable analysis those with any somatic mutations and C1/C2 heterozygosity had less acute graft-versus-host disease (GvHD) (hazard ratio [HR], 0. 32; 95% confidence interval [CI], 0. 14-0. 75; P = . 009), more relapse (HR, 3. 02; 95% CI, 1. 30-7. 01; P = . 010), inferior relapse-free survival (RFS; HR, 2. 22; 95% CI, 1. 17-4. 20; P = . 014), and overall survival (OS; HR, 2. 21; 95% CI, 1.

17-4. 20; P = . 015), whereas those with a missing KIR ligand had superior RFS (HR, 0. 53; 95% CI, 0. 30-0. 94; P = . 031). The presence of a somatic mutation and donor haplotype A was also associated with less acute GvHD (HR, 0. 38; 95% CI, 0. 16-0. 92; P = . 032), more relapse (HR, 2. 72; 95% CI, 1. 13-6. 52; P = . 025), inferior RFS (HR, 2. 11; 95% CI, 1. 07-4. 14; P = . 030), and OS (HR, 2. 20; 95% CI, 1.

11-4. 38; P = . 024). Enhanced NK cell alloreactivity from more KIR activating signals (donor B haplotype) and fewer inhibitory signals (recipient missing KIR ligand or C1 or C2 homozygosity) may help mitigate the adverse prognosis associated with some AML somatic mutations. These results may have implications for improving patient risk stratification prior to transplant and optimizing donor selection.

论文信息

作者
Hong S、Rybicki L、Zhang A、Thomas D、Kerr CM、Durrani J、Rainey MA、Mian A
第一作者单位
Department of Hematology and Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.United States
通讯作者单位
Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: sobeckr@ccf.org.United States
文献类型
观察性研究
期刊
Transplantation and cellular therapy2021 Nov
原文标识
PubMed 34380091 · DOI 10.1016/j.jtct.2021.08.002